Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

OSE

OSE Immunotherapeutics (OSE)

OSE Immunotherapeutics
Von:
Sortieren nach:
 Showing the most relevant articles for your search:EU:OSE
DatumZeitQuelleÜberschriftSymbolFirma
13/01/202518h00GlobeNewswire Inc.OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development OfficerEU:OSEOSE Immunotherapeutics
11/12/202418h00GlobeNewswire Inc.OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®EU:OSEOSE Immunotherapeutics
02/12/202418h00GlobeNewswire Inc.OSE Immunotherapeutics Strengthens Leadership and Executive CommitteeEU:OSEOSE Immunotherapeutics
04/11/202407h30GlobeNewswire Inc.OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative ColitisEU:OSEOSE Immunotherapeutics
17/10/202418h00GlobeNewswire Inc.OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic IndexEU:OSEOSE Immunotherapeutics
26/09/202418h00GlobeNewswire Inc.OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate UpdateEU:OSEOSE Immunotherapeutics
10/09/202407h30GlobeNewswire Inc.OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung CancerEU:OSEOSE Immunotherapeutics
24/07/202408h55GlobeNewswire Inc.OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative ColitisEU:OSEOSE Immunotherapeutics
03/07/202418h00GlobeNewswire Inc.OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancerEU:OSEOSE Immunotherapeutics
03/07/202418h00GlobeNewswire Inc.Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371EU:OSEOSE Immunotherapeutics
03/07/202418h00GlobeNewswire Inc.Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371EU:OSEOSE Immunotherapeutics
02/07/202418h00GlobeNewswire Inc.Informations relatives au nombre total de droits de vote et d’actions composant le capitalEU:OSEOSE Immunotherapeutics
01/07/202407h30GlobeNewswire Inc.OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’EU:OSEOSE Immunotherapeutics
01/07/202407h30GlobeNewswire Inc.OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ EU:OSEOSE Immunotherapeutics
01/07/202407h30GlobeNewswire Inc.OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’EU:OSEOSE Immunotherapeutics
24/06/202407h30GlobeNewswire Inc.OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell TherapiesEU:OSEOSE Immunotherapeutics
24/06/202407h30GlobeNewswire Inc.OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell TherapiesEU:OSEOSE Immunotherapeutics
24/06/202407h30GlobeNewswire Inc.OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-TEU:OSEOSE Immunotherapeutics
20/06/202407h30GlobeNewswire Inc.OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)EU:OSEOSE Immunotherapeutics
20/06/202407h30GlobeNewswire Inc.OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)EU:OSEOSE Immunotherapeutics
20/06/202407h30GlobeNewswire Inc.OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)EU:OSEOSE Immunotherapeutics
19/06/202418h15GlobeNewswire Inc.OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la SociétéEU:OSEOSE Immunotherapeutics
19/06/202418h15GlobeNewswire Inc.OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s GrowthEU:OSEOSE Immunotherapeutics
19/06/202418h15GlobeNewswire Inc.OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s GrowthEU:OSEOSE Immunotherapeutics
12/06/202418h00GlobeNewswire Inc.OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin BesseEU:OSEOSE Immunotherapeutics
12/06/202418h00GlobeNewswire Inc.OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin BesseEU:OSEOSE Immunotherapeutics
12/06/202418h00GlobeNewswire Inc.Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellulesEU:OSEOSE Immunotherapeutics
05/06/202407h30GlobeNewswire Inc.OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal TransplantEU:OSEOSE Immunotherapeutics
05/06/202407h30GlobeNewswire Inc.OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénaleEU:OSEOSE Immunotherapeutics
05/06/202407h30GlobeNewswire Inc.OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal TransplantEU:OSEOSE Immunotherapeutics
 Showing the most relevant articles for your search:EU:OSE

Kürzlich von Ihnen besucht

Delayed Upgrade Clock